Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study
ABSTRACT Introduction Gemtuzumab ozogamicin (GO), a CD33‐targeted antibody–drug conjugate, is approved in combination with daunorubicin/cytarabine for patients ≥ 15 years with de novo, CD33‐positive acute myeloid leukemia (AML). Methods This retrospective, observational study assessed real‐world use, clinical outcomes, and safety of GO in 113 patients with de novo AML treated between 2014 and 2022 in the French authorization for temporary use (ATU) and post‐ATU program. Results During first induction, most patients (98.1%; 105/107) received GO with other agents, mainly daunorubicin/cytarabine (60.0%; 63/105). After 44.6 months’ median follow‐up (95% CI: 33.8–69.3), 78.6% (88/112) responded; 72.3% (81/112) achieved complete response, 52.2% (24/46) without measurable residual disease. Median (95% CI) event‐free survival (EFS), relapse‐free survival (RFS), and overall survival (OS) were 13.1 months (9.9–17.5), 17.5 months (12.6–35.6), and 49.8 months (21.8–not estimable), respectively. Overall, 46.9% of patients died. Older age predicted shorter OS ( p < 0.001). FLT3‐TKD mutation ( p = 0.013) and adverse cytogenetic classification ( p = 0.015) predicted shorter EFS. ECOG performance status ≥ 2 ( p = 0.005) and adverse cytogenetic classification ( p = 0.001) predicted shorter RFS. Forty‐four patients (38.9%) reported ≥ 1 adverse event of interest; 13.3% were serious and 26.6% treatment‐related; most commonly thrombocytopenia (21.2%). GO was predominantly administered per indication. No new safety signals were reported. Conclusions Results demonstrate real‐world safety and clinical outcomes of GO plus induction therapy for patients with de novo CD33‐positive AML. Trial Registration EU Post Authorization Study (PAS) register number: EUPAS44551
Authors
- Thorsten Braun (ORCID: https://orcid.org/0000-0002-1989-9920)
- Maël Heiblig (ORCID: https://orcid.org/0000-0003-1682-8657)
- Delphine Lebon (ORCID: https://orcid.org/0000-0002-4073-1559)
- Anne Vekhoff (ORCID: https://orcid.org/0009-0003-0417-9706)
- Cécile Pautas (ORCID: https://orcid.org/0000-0002-3385-6484)
- Emmanuel Raffoux (ORCID: https://orcid.org/0000-0003-3925-7391)
- Juliette Lambert (ORCID: https://orcid.org/0000-0001-5142-0310)
- Karïn Gogat
- Alberto Santagostino
Institutions
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Sorbonne Université (FR)
- Université Sorbonne Paris Nord (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Saint-Antoine (FR)
- Hôpital Lyon Sud (FR)
- Pfizer (France) (FR)
- Centre Hospitalier de Troyes (FR)
- Hôpital Avicenne (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Hôpital Saint-Louis (FR)
- Centre Hospitalier de Versailles (FR)
Publication Details
- Journal
- eJHaem
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1002/jha2.70454
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00